Polyneuropathy

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Polyneuropathy
Vasculitic neuropathy - plastics - low mag.jpg
Micrograph showing peripheral neuropathy (vasculitis).Polyneuropathy is peripheral neuropathy occurring in the same area on both sides of the body.
Classification and external resources
Specialty neurology
ICD-10 G60-G64
ICD-9-CM 356.4, 357.1-357.7
Patient UK Polyneuropathy
MeSH D011115

Polyneuropathy (poly- + neuro- + -pathy) is damage or disease affecting peripheral nerves (peripheral neuropathy) in roughly the same areas on both sides of the body, featuring weakness, numbness, and burning pain.[1] It usually begins in the hands and feet and may progress to the arms and legs; and sometimes to other parts of the body where it may affect the autonomic nervous system. It may be acute or chronic. A number of different disorders may cause polyneuropathy, including diabetes and some types of Guillain-Barré syndrome.[2][3][4]

Classification[edit]

Polyneuropathies may be classified in different ways, such as by cause,[5] by presentation,[1] or by classes of polyneuropathy, in terms of which part of the nerve cell is affected mainly: the axon, the myelin sheath, or the cell body.[6][7]

Action potential propagation in myelinated neurons is faster than in unmyelinated neurons(left)

Signs/symptoms[edit]

Among the signs/symptoms of polyneuropathy, which can be divided (into sensory and hereditary) and are consistent with the following:[1]

Causes[edit]

The causes (etiology) of polyneuropathy can be divided into hereditary and acquired and are therefore as follows:[5]

Pathophysiology[edit]

Human T Cell

In regards to the pathophysiology of polyneuropathy, of course, the former depends on which polyneuropathy. For instance in the case of chronic inflammatory demyelinating polyneuropathy, one finds that it is a autoimmune disease. Here, T cells involvement has been demonstrated ,while in terms of demyelination, antibodies alone are not capable.[15]

Diagnosis[edit]

Micrograph of a muscle biopsy

The diagnosis of polyneuropathies begins with a history and physical examination to ascertain the pattern of the disease process (such as-arms, legs, distal, proximal) if they fluctuate, and what deficits and pain are involved. If pain is a factor, determining where and how long the pain has been present is important, one also needs to know what disorders are present within the family and what diseases the person may have. Although diseases often are suggested by the physical examination and history alone, tests that may be employed include: electrodiagnostic testing, serum protein electrophoresis, nerve conduction studies, urinalysis, serum creatine kinase (CK) and antibody testing (nerve biopsy is sometimes done).[1][16]

Other tests may be used, especially tests for specific disorders associated with polyneuropathies, quality measures have been developed to diagnose patients with distal symmetrical polyneuropathy (DSP).[17]

Differential diagnosis[edit]

In terms of the differential diagnosis for polyneuropathy one must look at the following:

Treatment[edit]

Methylprednisolone

In the treatment of polyneuropathies one must ascertain and manage the cause, among management activities are: weight decrease,use of a walking aid, and occupational therapist assistance.Additionally BP control in those with diabetes is helpful, while intravenous immunoglobulin is used for multifocal motor neuropathy.[1]

According to Lopate, et al methylprednisolone is a viable treatment for chronic inflammatory demyelinative polyneuropathy (which can also be treated with intravenous immunoglobulin) The author(s) also indicate that prednisone has greater adverse effects in such treatment, as opposed to intermittent (high-doses) of the aforementioned medication.[1][20]

According to Wu, et al in critical illness polyneuropathy supportive and preventive therapy are important for the affected individual, as well as, avoiding(or limiting) corticosteroids .[21]

See also[edit]

References[edit]

  1. ^ a b c d e f "Polyneuropathies. Medical inforamtion about polyneuropathy | Patient". Patient. Retrieved 2016-07-17. 
  2. ^ Richard A C Hughes (23 February 2002). "Clinical review: Peripheral neuropathy". British Medical Journal. 324: 466. doi:10.1136/bmj.324.7335.466. 
  3. ^ Janet M. Torpy; Jennifer L. Kincaid; Richard M. Glass (21 April 2010). "Patient page: Peripheral neuropathy". Journal of the American Medical Association. 303 (15). doi:10.1001/jama.303.15.1556. 
  4. ^ "Peripheral neuropathy fact sheet". National Institute of Neurological Disorders and Stroke. 19 September 2012. 
  5. ^ a b MD, Dr Sara J. Cuccurullo. Physical Medicine and Rehabilitation Board Review, Third Edition. Demos Medical Publishing. p. 434. ISBN 9781617052019. Retrieved 26 August 2016. 
  6. ^ Rakel, David; Rakel, Robert E. Textbook of Family Medicine. Elsevier Health Sciences. p. 1026. ISBN 9780323313087. Retrieved 26 August 2016. 
  7. ^ McCance, Kathryn L.; Huether, Sue E. Pathophysiology: The Biologic Basis for Disease in Adults and Children. Elsevier Health Sciences. p. 635. ISBN 9780323316071. Retrieved 26 August 2016. 
  8. ^ Perry, edited by Michael C. (2007). The chemotherapy source book (4th ed. ed.). Philadelphia, Pa.: Lippincott Williams & Wilkins. p. 241. ISBN 9780781773287. Retrieved 26 August 2016. 
  9. ^ Moloney, Elizabeth B.; de Winter, Fred; Verhaagen, Joost (14 August 2014). "ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease". Frontiers in Neuroscience. 8. doi:10.3389/fnins.2014.00252. Retrieved 26 August 2016. 
  10. ^ Wardlaw, Graeme J. Hankey, Joanna M.; Wardlaw, Joanna M. (2008). Clinical neurology. London: Manson. p. 580. ISBN 9781840765182. Retrieved 26 August 2016. 
  11. ^ Goodman, Catherine C.; Fuller, Kenda S. Pathology: Implications for the Physical Therapist. Elsevier Health Sciences. p. 1597. ISBN 9780323266468. Retrieved 26 August 2016. 
  12. ^ RESERVED, INSERM US14 -- ALL RIGHTS. "Orphanet: Acute inflammatory demyelinating polyradiculoneuropathy". www.orpha.net. Retrieved 2016-08-26. 
  13. ^ "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Information Page: National Institute of Neurological Disorders and Stroke (NINDS)". www.ninds.nih.gov. Retrieved 2016-07-30. 
  14. ^ Barohn, Richard J.; Amato, Anthony A. (May 2013). "Pattern-Recognition Approach to Neuropathy and Neuronopathy". Neurologic Clinics. 31 (2): 343–361. doi:10.1016/j.ncl.2013.02.001. ISSN 0733-8619. Retrieved 26 August 2016. 
  15. ^ Mahdi-Rogers, Mohamed; Rajabally, Yusuf A (1 January 2010). "Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins". Biologics : Targets & Therapy. 4: 45–49. ISSN 1177-5475. Retrieved 27 August 2016. 
  16. ^ Burns, Ted M.; Mauermann, Michelle L. (15 February 2011). "The Evaluation of Polyneuropathies". Neurology. 76 (7 Supplement 2): S6–S13. doi:10.1212/WNL.0b013e31820c3622. ISSN 0028-3878. Retrieved 26 August 2016. 
  17. ^ England, John D.; Franklin, Gary; Gjorvad, Gina; Swain-Eng, Rebecca; Brannagan, Thomas H.; David, William S.; Dubinsky, Richard M.; Smith, Benn E. (13 May 2014). "Quality improvement in neurology". Neurology. 82 (19): 1745–1748. doi:10.1212/WNL.0000000000000397. ISSN 0028-3878. Retrieved 17 July 2016. 
  18. ^ a b c d e f g h "Polyneuropathy/differential diagnosis". BMJ.com. BMJ Best Practices. Retrieved 26 August 2016. 
  19. ^ Chronic renal failure, Medline Plus
  20. ^ Lopate, Glenn; Pestronk, Alan; Al-Lozi, Muhammad (1 February 2005). "Treatment of Chronic Inflammatory Demyelinating Polyneuropathy With High-Dose Intermittent Intravenous Methylprednisolone". Archives of Neurology. 62 (2): 249. doi:10.1001/archneur.62.2.249. ISSN 0003-9942. Retrieved 26 August 2016. 
  21. ^ Zhou, Chunkui; Wu, Limin; Ni, Fengming; Ji, Wei; Wu, Jiang; Zhang, Hongliang (1 January 2014). "Critical illness polyneuropathy and myopathy: a systematic review". Neural Regeneration Research. 9 (1): 101–110. doi:10.4103/1673-5374.125337. ISSN 1673-5374. Retrieved 26 August 2016. 

Further reading[edit]